CD133 negatively regulates tumorigenicity via AKT pathway in synovial sarcoma

Taichi Kimura, Lei Wang, Kouichi Tabu, Hiroshi Nishihara, Yuji Mashita, Naoyuki Kikuchi, Mishie Tanino, Hiroaki Hiraga, Shinya Tanaka

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Synovial sarcoma (SS) is an aggressive tumor that accounts for almost 10 of all soft tissue sarcomas. In this study, we found the expression of CD133 in human SS specimens, thus, we focused on the function of CD133 in SS. Separation of the CD133-positive and -negative subpopulations in SS cell lines clarified that the CD133-negative subpopulation exhibited enhanced growth and hyperphosphorylation of AKT. Treatment of Akt inhibitor suppressed the cell growth of CD133-negative subpopulation to the levels of CD133-positive cells. These results suggest that CD133 has negative effect on the growth of cells through AKT-dependent signalling pathway.

Original languageEnglish
Pages (from-to)390-397
Number of pages8
JournalCancer Investigation
Volume30
Issue number5
DOIs
Publication statusPublished - 2012 Jun

Keywords

  • CD133
  • Cancer stem cell
  • Synovial sarcoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'CD133 negatively regulates tumorigenicity via AKT pathway in synovial sarcoma'. Together they form a unique fingerprint.

  • Cite this

    Kimura, T., Wang, L., Tabu, K., Nishihara, H., Mashita, Y., Kikuchi, N., Tanino, M., Hiraga, H., & Tanaka, S. (2012). CD133 negatively regulates tumorigenicity via AKT pathway in synovial sarcoma. Cancer Investigation, 30(5), 390-397. https://doi.org/10.3109/07357907.2012.672607